SEC Filing Summary
Important entity mismatch: The supplied filing is Trail One, Inc.’s Form 10-K, not a filing for Citius Pharmaceuticals, Inc. It reports the fiscal year ended September 30, 2013; it does not provide standalone fourth-quarter results.
Business context and reporting period
Trail One was a development-stage company pursuing customized, cosmetic automobile license-plate tags. It had not launched sales or generated revenue. On May 24, 2013, Mohammad Omar Rahman acquired the former controlling shareholder’s 10 million shares, representing about 55.6%, and became CEO and a director. The company was also negotiating a possible reverse merger on a non-binding basis.
Financial results and liquidity
| Metric | FY ended Sep. 30, 2013 | FY ended Sep. 30, 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $28,118 | $19,618 |
| Interest expense | $3,251 | $2,388 |
| Net loss | $31,369 | $22,006 |
| Cash used in operating activities | $20,604 | $20,324 |
| Cash provided by financing activities | $20,469 | $20,247 |
- Net loss widened by $9,363, approximately 43%; higher professional fees drove the increase in operating expenses.
- At September 30, 2013, cash was $0, total assets were $0, current liabilities were $14,694, and working capital and stockholders’ equity were each negative $14,694. The prior-year working-capital deficit was $45,847.
- Accumulated deficit was $95,216, versus $63,847 a year earlier. No profit, positive operating cash flow, or meaningful margin was reported.
- During 2013, the former CEO/shareholder forgave $62,522 of debt, advances and related amounts, recorded as additional paid-in capital; $2,700 of accounts payable and accrued liabilities was also separately described as forgiven. The filing reports $3,200 of third-party notes payable and $11 of accrued non-related-party interest at year-end, in addition to accounts payable and a $9 bank overdraft.
- In December 2013, Highline Research Advisors LLC advanced $17,523 in unsecured, demand loans at 8% interest.
Outlook, risks and unusual items
- Management said existing liquidity would not fund operations for the next 12 months and expected revenue to be insufficient to cover expenses. It cited a monthly burn rate of about $2,614 and anticipated further financing needs.
- Management planned to seek equity or debt financing and also identified product sales, bank financing, and a possible reverse merger as potential funding or business paths. Financing availability and acceptable terms were uncertain; failure to obtain funds could force the company to curtail or cease operations.
- The auditor’s report and management’s disclosures raised substantial doubt about the company’s ability to continue as a going concern. The financial statements were not adjusted for possible consequences if the company could not continue.
- The proposed reverse merger was not binding or assured; it could involve issuing shares, a change in control, and assumption of the acquired business’s liabilities.
- The company disclosed that its disclosure controls and procedures were ineffective, citing no independent board or audit committee, inadequate segregation of duties, and reliance on a financial consultant for financial reporting.
- Other risks included no established trading market, potential dilution from future financing, reliance on a prospective manufacturer with whom the company had no agreement, and a controlling shareholder’s ability to influence corporate matters. No material legal proceedings were identified.
Most important facts for investors to verify
- Confirm the issuer identity: this filing is for Trail One, Inc., not Citius Pharmaceuticals, Inc.
- Verify whether the non-binding reverse-merger discussions proceeded and whether any transaction or change of control occurred.
- Check subsequent filings for financing, outstanding liabilities, cash runway, and any changes to the going-concern status.
- Review the debt-forgiveness disclosures and related-party transactions, including the reported year-end liabilities and post-year-end loans.
- Check whether the company addressed the disclosed ineffective controls and whether a public trading market developed.